Enterolactone and asthma

NIH RePORTER · NIH · K23 · $192,839 · view on reporter.nih.gov ↗

Abstract

Project Summary/Abstract 1  This proposal details a 5-yr plan to prepare the candidate, Juan C. Cardet MD, for a career as an 2  independent, translational investigator positioned to impact our understanding of asthma. The aim is to clarify 3  the relationship between enterolactone and asthma through complementary clinical and basic strategies. 4  Lignans are dietary, plant-derived chemicals with anti-inflammatory and antioxidant properties. Enterolactone 5  is the end product of human gut bacterial metabolism of lignans. Differences in gut microbiome composition 6  categorize patients into high- vs. low-enterolactone producers. This group reported concentration-dependent 7  inverse associations between enterolactone and asthma in a nationally-representative cohort (NHANES); but 8  this study is limited by its cross-sectional design and incomplete clinical characterization. We hypothesize 9  that enterolactone's inverse relationship with asthma is driven by its anti-inflammatory and anti- 10  oxidative properties. The candidate will clarify whether enterolactone has a clinically-evident relationship 11  with asthma by analyzing data from the NHLBI Severe Asthma Research Program's (SARP) prospective 12  study. As a founding partnership in SARP, our group has access to stored biospecimens and participants' 13  clinical, biochemical, and physiological data collected during 3 years of follow-up. Further, the candidate 14  will employ in vitro and in vivo approaches to determine enterolactone's effects on human airway structural 15  cells and murine models of asthma. Preliminary data by Cardet et al suggest that enterolactone may have 16  anti-inflammatory effects on A549 human airway epithelial cells, observations this group will extend through 17  this proposal. Clinical findings will steer the focus of laboratory experiments, and reversely, discoveries at the 18  bench will generate clinical questions. At this project's conclusion, the candidate will be skillful with (1) 19  sophisticated biostatistical analyses on clinical datasets such as SARP's; and with designing, conducting, and 20  interpreting experiments on (2) airway structural cells (3) and murine models of asthma. 21  During the award period, the candidate will leverage his clinical experience with asthma, regular exposure to 22  NIH research networks, and structured academics at the HSPH's MPH program. This training will allow him to 23  transition to independence during the 4-5th years of the award. Dr. Cardet will work under the 1° mentorship of 24  Dr. Elliot Israel, an expert in translation asthma research with an excellent mentoring record. He will have as 25  co-mentors Drs. Quan Lu and Stephanie Shore, who will train Dr. Cardet to master the basic experiments 26  described herein (see `Research Strategy, Aim 2'). Further, Dr. Cardet has assembled a team of 27  extraordinary physician-scientists (Drs. Joshua Boyce, Bruce Levy, and Wanda Phipatanakul), who have 28  committed ...

Key facts

NIH application ID
9846187
Project number
5K23AI125785-05
Recipient
UNIVERSITY OF SOUTH FLORIDA
Principal Investigator
Juan Carlos Cardet
Activity code
K23
Funding institute
NIH
Fiscal year
2020
Award amount
$192,839
Award type
5
Project period
2017-02-15 → 2022-01-31